Antibiofilm Efficacy of DispersinB(®) Wound Spray Used in Combination with a Silver Wound Dressing.
Chronic wounds including diabetic foot ulcers, pressure ulcers, and venous leg ulcers are a worldwide health problem. As the traditional methods of treatment have proven ineffective against chronic wounds involving biofilms, there is an unmet clinical need for developing products with an antibiofilm component that inhibits and/or disrupts biofilms and thus make the biofilm-embedded bacteria more susceptible to antimicrobial therapy. We developed a DispersinB® antibiofilm enzyme-based wound spray for treating chronic wounds in conjunction with an antimicrobial. Under in vitro conditions, the DispersinB® and Acticoat™ combination performed significantly better (P < 0.05) than Acticoat™ alone, indicating the synergy between the two compounds because of DispersinB® enhancing the antimicrobial activity of Acticoat™. Furthermore, DispersinB® wound spray enhanced the antimicrobial activity of Acticoat™ in a chronic wound mouse model of methicillin-resistant Staphylococcus aureus (MRSA) infection. Thus, this novel combination of DispersinB® and Acticoat™, an antimicrobial dressing, prompts clinical evaluation for potential applications in biofilm-based chronic wound management.
Kane Biotech Inc., Winnipeg, MB, Canada.
Purushottam V
PV
Gawande
Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Allie P
AP
Clinton
Kane Biotech Inc., Winnipeg, MB, Canada.
Karen
K
LoVetri
Kane Biotech Inc., Winnipeg, MB, Canada.
Nandadeva
N
Yakandawala
Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Kendra P
KP
Rumbaugh
Kane Biotech Inc., Winnipeg, MB, Canada.
Srinivasa
S
Madhyastha
DispersinB®; MRSA; biofilm; chronic wound; silver